JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to bargain according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral to an Overweight rating, boosting the terms people to $11 from $10. The alteration follows the coagulated results of Recursion’s MEK 1/2 inhibitor, REC-4881, which showed potent effectiveness successful FAP patients during the TUPELO trial.

After 12 weeks of treatment, the proceedings showed a 43% median simplification successful full polyp burden, with 75% of evaluable patients experiencing reductions. Notably, 82% of patients sustained unchangeable decreases 12 weeks aft discontinuing medication, with a median simplification of 53% from baseline.

JPMorgan sees explosive imaginable for REC-4881 successful the United States, projecting highest income of much than $1 cardinal with a 60% accidental of success. These objective outcomes, arsenic good arsenic pharmaceutical agreements that person produced much than $500 cardinal successful milestone payments to date, person helped to corroborate Recursion’s AI-driven pipeline.

According to the firm’s study, increasing diligent groups, stronger penetration rates, and pricing mightiness each supply further upside for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX).

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the usage of artificial quality and instrumentality learning to accelerate cause discovery, with a absorption connected uncommon diseases and oncology.

While we admit the imaginable of RXRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.